Hunter Capital reported, as planned, virtually no revenue in the first quarter. Net profit increased slightly. Ebitda amounted to SEK -0.8 million (-0.9 million). Profit after tax was SEK 1.9 million (1.1 million), an increase of 72.7 percent compared with the previous year. Earnings per share amounted to SEK 0.42 (0.25). Cash and cash equivalents amounted to SEK 0.3 million (4.3 million).During the past quarter, Hunter Capital focused on strengthening the investment platform and refining the selection processes ahead of the next growth phase, according to acting CEO Jacob Eriksson. The company sees a market where capital is becoming more selective and where quality is prioritized over quantity, which the company says favors investments with clear catalysts and realistic opportunities for value creation.He further points out that portfolio company Hunter Capital RTO 1 has entered into a letter of intent regarding a reverse listing of Danish ResoTher Pharma. The proposed transaction implies a valuation of approximately SEK 365–405 million for the combined company. "The process is subject to customary steps, but it clearly illustrates our ability to identify and drive deals where structural value can be made visible," Eriksson states. The company also says that the number of structural transactions and repositionings in the market is increasing, creating new investment opportunities where flexibility and experience can contribute to value creation.Hunter Capital, SEK millionQ1-2026Q1-2025ChangeNet sales0.00.0Ebitda-0.8-0.9Net profit1.91.172.7%Earnings per share, SEK0.420.2568.0%Cash and cash equivalents0.34.3-93.0%